Team:Slovenia/Society

From 2012.igem.org

(Difference between revisions)
 
(20 intermediate revisions not shown)
Line 2: Line 2:
<head>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
 +
<!-- back to top -->
 +
<div style="position:fixed; bottom:45px; right:30px; width:100px; height:66px; background-color:transparent;">
 +
<a href="#topofthepage">
 +
<table style="background-color:transparent;" onclick="window.location = '#topofthepage'" class="invisible" style="height:100%;">
 +
<tr class="invisible" style="background-color:transparent;">
 +
<td class="invisible" style="background-color:transparent;" valign="center">
 +
<img width="100px" src ="https://static.igem.org/mediawiki/2012/1/14/Svn12_hp_btt.png"></img>
 +
</td></tr></table>
 +
</a>
 +
</div>
<style type="text/css">
<style type="text/css">
Line 201: Line 211:
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
 +
#cssmenu ul li > ul li a table tr td span{ outline:none; display:block; position:relative; margin:0; padding:0px 0px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }
#cssmenu, #cssmenu > ul > li > ul > li a:hover
#cssmenu, #cssmenu > ul > li > ul > li a:hover
{ background:#043A6B;  
{ background:#043A6B;  
Line 216: Line 227:
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
/* end CSS navigation menu (blue) */
/* end CSS navigation menu (blue) */
 +
 +
/*new table start*/
 +
table.newtable {background-color:transparent;}
 +
td.newtable, th.newtable {background-color:transparent;}
 +
thead.newtable{ }
 +
tbody .newtable{}
 +
/*new table*/
 +
 +
Line 292: Line 312:
<body>
<body>
 +
<a name="topofthepage" style="background-color:transparent;"></a>
<div id="banner">
<div id="banner">
-
<a style="position:absolute; top:0px; left:490px;" href="https://2012.igem.org/Main_Page"><b>iGEM 2012</b></a>
 
</div>
</div>
Line 316: Line 336:
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><tr class="newtable"><td class="newtable"><span>Positive feedback loop switch</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchControls'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><tr class="newtable"><td class="newtable"><span>Controls</span></td><td class="newtable"><img style="margin-right:-81px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 324: Line 345:
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation'><span>Microcapsule degradation</span></a></li>  
+
    <li><a href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation"><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><tr class="newtable"><td class="newtable"><span>Microcapsule degradation</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 332: Line 353:
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationImpact'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><tr class="newtable"><td class="newtable"><span>Impact</span></td><td class="newtable"><img style="margin-right:-86px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 
 
  </ul>
  </ul>
Line 339: Line 361:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><span>Pharmacokinetics</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><tr class="newtable"><td class="newtable"><span>Pharmacokinetics</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><span>Quantitative and stability model</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><tr class="newtable"><td class="newtable"><span>Experimental model</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><span>Interactive simulations</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Interactive simulations</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
  </ul>
  </ul>
</li>
</li>
Line 355: Line 377:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><span>Lablog</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><tr class="newtable"><td class="newtable"><span>Lablog</span></td><td class="newtable"><img style="margin-right:-90px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
  </ul>
  </ul>
Line 378: Line 400:
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
 +
<li><a href='https://2012.igem.org/Team:Slovenia/TeamCollaborations'><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Collaborations</span></td><td class="newtable"><img style="margin-right:-20px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
Line 385: Line 408:
</div>
</div>
<!-- end main menu -->
<!-- end main menu -->
 +
</div> <!-- end menu -->
</div> <!-- end menu -->
<div id="main">
<div id="main">
 +
 +
 +
<!-- dummy link na bannerju -->
 +
<a href="https://2012.igem.org/Main_Page">
 +
<div id="dummy" style="background-color:transparent; position:absolute; left:870px; top:25px; width:115px; height:80px; z-index:100; opacity:0.0;">
 +
</div>
 +
</a>
 +
<br/>
<br/>
<!-- VSEBINA OD TU DALJE -->
<!-- VSEBINA OD TU DALJE -->
<h1>Human practice</h1>
<h1>Human practice</h1>
 +
<br />
 +
 +
<table class="summary">
 +
<tbody class="summary">
 +
<tr class="summary">
 +
<td class="summary">
<p>We believe that biomedical applications of synthetic biology have great potential in improving human health in the twenty-first century. </p>
<p>We believe that biomedical applications of synthetic biology have great potential in improving human health in the twenty-first century. </p>
<p>We discussed not only the scientific and medical but also ethical, legal, environmental and other social aspects of our project with experts from different fields. </p>
<p>We discussed not only the scientific and medical but also ethical, legal, environmental and other social aspects of our project with experts from different fields. </p>
-
<p>Physicians, patients, students, journalists, scientists and members of the general public shared their views and attitudes toward synthetic biology with us. A large majority of them expressed enthusiasm for the potential medical application of our project but also provided valuable information on which aspects of the project could be perceived as risky. </p>
+
<p>Physicians, patients, students, journalists, scientists and members of the general public shared their views and attitudes towards synthetic biology with us. A large majority of them expressed enthusiasm for the potential medical application of our project but also provided valuable information on the aspects of the project could be perceived as a risk. </p>
-
<p>We also established connections with a network of high schools in Slovenia, many of them in the areas that don't have the possibility for a direct contact with scientific organizations, to introduce synthetic biology and its many potential uses to younger generations. </p>
+
<p>We also established a network of links to high schools in Slovenia, many of them in the areas that don't have the possibility for a direct contact with scientific organizations, in order to introduce the idea of synthetic biology and its many potential uses to younger generations. </p>
-
<br/>
+
</td>
-
<img src="X"></img>
+
</tr>
-
<p><b>Figure 1. Participation of all stakeholders to exploit the advantages of synthetic biology.</b></p>
+
</tbody>
 +
</table>
 +
 
 +
<p>We are aware that <b>social aspects</b> of synthetic biology are important for the<b> successful clinical implementation of synthetic biology</b> in the future. Safety, regulations, ethics, cost, efficiency and acceptance are all important also to our project (Figure 1). </p>
 +
 
 +
<img style="width:607px;" src="https://static.igem.org/mediawiki/2012/3/32/Svn12_society_human_practice_fig2.png"></img>
 +
<p style="text-align:center;"><b>Figure 1. Different social aspects that can affect the success of therapy based on synthetic biology. </b>
<br/>
<br/>
-
<img src="X"></img>
+
 
-
<p><b>Figure 2. Safety, regulations and other aspects important for our project. </b>
+
 
-
<br/>
+
 
-
<p>Our goal was to make a contribution to the field of therapy of different accute conditions. Although our study shows promising results and the therapeutic implementation of such a system seems tempting, we realize that for the actual realization of our idea, it is necessary not only to collaborate with professionals from different fields but also to take into account the views and concerns of the broader public. </p>
+
<p>Our goal was to make a contribution to the medicine. Although our study shows promising results and the therapeutic implementation of such a system seems tempting, we realize that for the actual implementation of our idea, it is necessary not only to collaborate with professionals from different fields but also to take into account the views and concerns of the broader public. </p>
-
<p>For this reason we organized various meetings regarding medical, ethical, regulatory and other questions (Figure 1):  
+
<p>For this reason we organized meetings with different stakeholders regarding medical, ethical, regulatory and other questions (Figure 2):  
-
<ol type="a">
+
<ul style="padding-left:30px">
-
<li>Meetings with <b>physicians</b> whose specialties are the diseases and therapy which we thought might benefit from the application of synthetic biology. An infectiologist, specialist for a viral hepatitis, a specialist for surgical wound healing, a cardiologist and an interventional radiologist advised us on the opportunities to implement our envisioned therapy, on best envisioned practices for the introduction of microcapsules into the body and potential dangers. </li>
+
<li>Meetings with <b>physicians</b> whose specialties are the diseases and therapies which we thought might benefit from the application of synthetic biology. A specialist for viral hepatitis, a specialist for surgical wound healing, a cardiologist and an interventional radiologist advised us on the opportunities to implement our envisioned therapy, on the best envisioned practices for the introduction of microcapsules into the body and on potential dangers. </li>
<li>We met with <b>patients</b> with viral hepatitis C and asked them about their views on the envisioned therapy and other applications of synthetic biology. </li>
<li>We met with <b>patients</b> with viral hepatitis C and asked them about their views on the envisioned therapy and other applications of synthetic biology. </li>
-
<li>we correspondeded with <b>the president of the Slovenian Medical Ethics Committee</b>.</li>
+
<li>We corresponded with <b>the president of the Slovenian Medical Ethics Committee</b>.</li>
-
<li>we performed a <b>survey of the perception of synthetic biology and our project</b> mainly within the student population and within the <b>journalists</b> that can strongly influence the public attitude towards application of new technologies</li>
+
<li>We met with a representative from <b>the Ministry of Agriculture and the Environment responsible for biosafety</b>.</li>
-
<li>we established a network of high schools in Slovenia with a plan to disseminate the idea and results of the project and synthetic biology in general to Slovenian <b>high school students</b> and their teachers and attract them to this fascinating area. </ol>
+
<li>We performed a <b>survey of the perception of synthetic biology and our project</b> mainly within the <b>student</b> population and among <b>journalists</b> that can strongly influence the public attitude towards applications of new technologies.</li>
 +
<li>We established a network of links with high schools in Slovenia in order to disseminate the idea and results of the project and synthetic biology in general to Slovenian <b>high school students and their teachers</b> and attract them to this fascinating area of research. </ul>
<br/>
<br/>
-
<p>We are aware that <b>social aspects</b> of synthetic biology are important for the<b> successful clinical implementation of synthetic biology</b> in the future. Safety, regulations, ethics, cost, efficiency and acceptance are all important also for our project (Figure 2). We are grateful to all the people who took their time to talk to us or to participate in our survey. </p>
+
<img src="https://static.igem.org/mediawiki/2012/8/88/Society6_4okt12.png" style="width:607px;"></img>
 +
<p style="text-align:center;"><b>Figure 2. Participation of all stakeholders to exploit the advantages of synthetic biology.</b></p>
 +
<br/>
 +
 
 +
<p>We are grateful to all the people who took their time to talk to us or to participate in our survey. </p>
 +
 
 +
 
 +
<hr>
 +
<b>
 +
Next: <a href='https://2012.igem.org/Team:Slovenia/SocietyScientists'>Scientists >></a>
 +
</b>
<!-- KONEC VSEBINE -->
<!-- KONEC VSEBINE -->

Latest revision as of 20:49, 26 October 2012


Human practice


We believe that biomedical applications of synthetic biology have great potential in improving human health in the twenty-first century.

We discussed not only the scientific and medical but also ethical, legal, environmental and other social aspects of our project with experts from different fields.

Physicians, patients, students, journalists, scientists and members of the general public shared their views and attitudes towards synthetic biology with us. A large majority of them expressed enthusiasm for the potential medical application of our project but also provided valuable information on the aspects of the project could be perceived as a risk.

We also established a network of links to high schools in Slovenia, many of them in the areas that don't have the possibility for a direct contact with scientific organizations, in order to introduce the idea of synthetic biology and its many potential uses to younger generations.

We are aware that social aspects of synthetic biology are important for the successful clinical implementation of synthetic biology in the future. Safety, regulations, ethics, cost, efficiency and acceptance are all important also to our project (Figure 1).

Figure 1. Different social aspects that can affect the success of therapy based on synthetic biology.

Our goal was to make a contribution to the medicine. Although our study shows promising results and the therapeutic implementation of such a system seems tempting, we realize that for the actual implementation of our idea, it is necessary not only to collaborate with professionals from different fields but also to take into account the views and concerns of the broader public.

For this reason we organized meetings with different stakeholders regarding medical, ethical, regulatory and other questions (Figure 2):

  • Meetings with physicians whose specialties are the diseases and therapies which we thought might benefit from the application of synthetic biology. A specialist for viral hepatitis, a specialist for surgical wound healing, a cardiologist and an interventional radiologist advised us on the opportunities to implement our envisioned therapy, on the best envisioned practices for the introduction of microcapsules into the body and on potential dangers.
  • We met with patients with viral hepatitis C and asked them about their views on the envisioned therapy and other applications of synthetic biology.
  • We corresponded with the president of the Slovenian Medical Ethics Committee.
  • We met with a representative from the Ministry of Agriculture and the Environment responsible for biosafety.
  • We performed a survey of the perception of synthetic biology and our project mainly within the student population and among journalists that can strongly influence the public attitude towards applications of new technologies.
  • We established a network of links with high schools in Slovenia in order to disseminate the idea and results of the project and synthetic biology in general to Slovenian high school students and their teachers and attract them to this fascinating area of research.

Figure 2. Participation of all stakeholders to exploit the advantages of synthetic biology.


We are grateful to all the people who took their time to talk to us or to participate in our survey.


Next: Scientists >>